We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

20 hedge funds and large institutions have $790K invested in Moleculin Biotech in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding

Funds holding: 16 → 20 (+4)

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

0.06% less ownership

Funds ownership: 0.65% → 0.58% (-0.06%)

40% less capital invested

Capital invested by funds: $1.31M → $790K (-$518K)

Holders
20
Holders Change
+4
Holders Change %
+25%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
5
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$66.8K
2
UBS Group
UBS Group
Switzerland
+$21.7K
3
LPL Financial
LPL Financial
California
+$12.4K
4
TRCT
Tower Research Capital (TRC)
New York
+$5.39K
5
Renaissance Technologies
Renaissance Technologies
New York
+$1.21K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$98.1K
2
AWM
Atticus Wealth Management
Florida
-$1.33K
3
BlackRock
BlackRock
New York
-$242
4
Bank of America
Bank of America
North Carolina
-$121
5
Morgan Stanley
Morgan Stanley
New York
-$61
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$540K +$66.8K +1,103 +10%
LPL Financial
2
LPL Financial
California
$70.1K +$12.4K +205 +14%
Vanguard Group
3
Vanguard Group
Pennsylvania
$52.6K -$98.1K -1,619 -57%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$37.5K +$485 +8 +0.9%
BlackRock
5
BlackRock
New York
$21K -$242 -4 -0.8%
Renaissance Technologies
6
Renaissance Technologies
New York
$19.5K +$1.21K +20 +5%
Truist Financial
7
Truist Financial
North Carolina
$17.9K – – –
UBS Group
8
UBS Group
Switzerland
$15.2K +$21.7K +358 New
TRCT
9
Tower Research Capital (TRC)
New York
$6.84K +$5.39K +89 +124%
AWM
10
Atticus Wealth Management
Florida
$4.73K -$1.33K -22 -17%
NFSG
11
Newbridge Financial Services Group
Florida
$2.32K – – –
Morgan Stanley
12
Morgan Stanley
New York
$724 -$61 -1 -6%
SS
13
SBI Securities
Japan
$689 +$969 +16 New
BWL
14
Bogart Wealth LLC
Virginia
$510 +$727 +12 New
Bank of America
15
Bank of America
North Carolina
$176 -$121 -2 -33%
SSB
16
Sandy Spring Bank
Maryland
$152 – – –
Osaic Holdings
17
Osaic Holdings
Arizona
$83 +$61 +1 +100%
CFO
18
CVA Family Office
Colorado
$58 – – –
KIM
19
Kestra Investment Management
Texas
$43 +$61 +1 New
NSIM
20
North Star Investment Management
Illinois
$29 – – –
DB
21
Danske Bank
Denmark
– -$6 – –
JP Morgan Chase
22
JP Morgan Chase
New York
– -$3 – –

MBRX Hedge Fund Activity: Q4 2024 in Review

20 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2024, worth a combined $790K — down 40% from $1.31M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new MBRX positions and 0 closed out — a net gain of 4 holders — while 6 added to existing stakes and 5 trimmed.

The largest buyer was Armistice Capital, adding an estimated $66.8K. The largest seller was Vanguard Group, cutting an estimated $98.1K.

  • 20 institutional investors held Moleculin Biotech (MBRX) as of Q4 2024, up from 16 in Q3 2024.
  • Funds reported $790K of Moleculin Biotech stock for Q4 2024, down 40% quarter-over-quarter.
  • 4 funds opened new Moleculin Biotech positions in Q4 2024 and 0 closed out, a net change of +4 holders.
  • The largest Moleculin Biotech buyer in Q4 2024 was Armistice Capital, an estimated $66.8K added.
  • The largest Moleculin Biotech seller in Q4 2024 was Vanguard Group, an estimated $98.1K sold.

Based on aggregated 13F filings for Q4 2024.